Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dual Time Point FDG-PET to Differentiate Between Recurrent Brain Tumor and Radionecrosis

NCT02391246 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT02391246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02391246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dual Time Point FDG-PET to Differentiate Between Recurrent Brain Tumor and Radionecrosis
Lead sponsor
Ottawa Hospital Research Institute
Phase
Observational
Overall status
Unknown status
Start date
June 30, 2015
Completion date
March 31, 2020
Enrollment
62 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant glioma